JP2025501452A - ヒトメソテリン結合物質 - Google Patents

ヒトメソテリン結合物質 Download PDF

Info

Publication number
JP2025501452A
JP2025501452A JP2024533052A JP2024533052A JP2025501452A JP 2025501452 A JP2025501452 A JP 2025501452A JP 2024533052 A JP2024533052 A JP 2024533052A JP 2024533052 A JP2024533052 A JP 2024533052A JP 2025501452 A JP2025501452 A JP 2025501452A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501452A5 (enExample
Inventor
フリードマン，アーサー
ハンダ，マサヒサ
シエ，チュン－ミン
シン，スジャータ
ダブリジファルド，サハバ
ヴェネガス，サンドラ・イザベル
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2025501452A publication Critical patent/JP2025501452A/ja
Publication of JP2025501452A5 publication Critical patent/JP2025501452A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024533052A 2021-12-10 2022-12-09 ヒトメソテリン結合物質 Pending JP2025501452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288162P 2021-12-10 2021-12-10
US63/288,162 2021-12-10
PCT/US2022/081253 WO2023108114A2 (en) 2021-12-10 2022-12-09 Human mesothelin binders

Publications (2)

Publication Number Publication Date
JP2025501452A true JP2025501452A (ja) 2025-01-22
JP2025501452A5 JP2025501452A5 (enExample) 2025-12-15

Family

ID=86731328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533052A Pending JP2025501452A (ja) 2021-12-10 2022-12-09 ヒトメソテリン結合物質

Country Status (8)

Country Link
EP (1) EP4444757A4 (enExample)
JP (1) JP2025501452A (enExample)
KR (1) KR20240114766A (enExample)
CN (1) CN118660911A (enExample)
AU (1) AU2022407541A1 (enExample)
CA (1) CA3239553A1 (enExample)
MX (1) MX2024007054A (enExample)
WO (1) WO2023108114A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2195017T1 (sl) * 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
PE20170917A1 (es) * 2010-12-20 2017-07-12 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA3063362A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease

Also Published As

Publication number Publication date
EP4444757A2 (en) 2024-10-16
WO2023108114A2 (en) 2023-06-15
CA3239553A1 (en) 2023-06-15
CN118660911A (zh) 2024-09-17
KR20240114766A (ko) 2024-07-24
WO2023108114A3 (en) 2024-04-04
EP4444757A4 (en) 2026-04-15
AU2022407541A1 (en) 2024-06-13
MX2024007054A (es) 2024-09-04

Similar Documents

Publication Publication Date Title
KR102871856B1 (ko) c-Kit에 대한 인간화 항체
US20160009824A1 (en) Tetravalent bispecific antibodies
US20230374130A1 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
TW201302790A (zh) 單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體
US20210388106A1 (en) Heavy chain antibodies binding to cd38
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
US20250230248A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
EP2844288B1 (en) Binding proteins having tethered light chains
EP4292610A1 (en) Variant antibodies that bind gamma-delta t cell receptors
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
KR20250130296A (ko) 항-ccr8 항체 및 이의 용도
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
US20240002533A1 (en) Arginase 1 binders for inhibiting arginase 1 activity
KR20240114766A (ko) 인간 메소텔린 결합제
HK40116952A (zh) 人间皮素结合剂
US20240301051A1 (en) Anti-cldn6 antibodies and methods of use
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2026060339A1 (en) Human claudin 18.2 binders and uses thereof
US20240002535A1 (en) Arginase 1 binders for inhibiting arginase 1 activity
WO2025206223A1 (ja) 抗ヒトクローディン１８．２抗体及びその使用
KR20250124805A (ko) Cd24에 대한 항체 및 이의 용도
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
EA053202B1 (ru) Антитела, которые связывают гамма-дельта т-клеточные рецепторы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251205